Scarica l'app Stockscreener
2.4832
7.73%
0.1782
Dopo l'orario di chiusura:
2.56
0.0768
+3.09%
Precedente Chiudi:
$2.305
Aprire:
$2.2586
Volume 24 ore:
30,811
Relative Volume:
2.63
Capitalizzazione di mercato:
$26.01M
Reddito:
-
Utile/perdita netta:
$-3.15M
Rapporto P/E:
-12.00
EPS:
-0.2069
Flusso di cassa netto:
$-2.23M
1 W Prestazione:
-3.00%
1M Prestazione:
+30.43%
6M Prestazione:
+20.84%
1 anno Prestazione:
-38.69%
Intervallo 1D:
$2.25
$2.58
Intervallo di 1 settimana:
$2.13
$2.58
Portata 52W:
$1.20
$5.50
Cytomed Therapeutics Ltd Stock (GDTC) Company Profile
Nome
Cytomed Therapeutics Ltd
Settore
Industria
Telefono
-
Indirizzo
-
Cytomed Therapeutics Ltd Borsa (GDTC) Ultime notizie
Discovering Penny Stocks On US Exchanges: 3 Picks Under $100M Market Cap - Simply Wall St
Osteopore Partners with CytoMed in Regenerative Medicine - TipRanks
Osteopore partners with NASDAQ-listed CytoMed to advance MSC-powered regeneration - Biotech Dispatch
CytoMed begins clinical trial for innovative cancer therapy - Investing.com
CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed’s strategy to cord blood-derived biologics through subsidiary, LongevityBank - Marketscreener.com
Cytomed Therapeutics announces NMRC co-funding support for ANGELICA trial - TipRanks
CytoMed Launches Innovative CAR-T Cell Trial - TipRanks
CytoMed begins clinical trial for innovative cancer therapy By Investing.com - Investing.com South Africa
CytoMed Therapeutics’ first-in-human Phase I ANGELICA - GlobeNewswire
CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant - StockTitan
CytoMed Acquires Cord Blood Assets, Eyes Regenerative Medicine - Yahoo Finance
CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed's strategy to cord blood-derived biologics through subsidiary, LongevityBank - The Manila Times
CytoMed Therapeutics completes cash acquisition of Cord - GlobeNewswire
GDTCCytoMed Therapeutics Limited Ordinary Shares Latest Stock News & Market Updates - StockTitan
CYTOMED THERAPEUTICS : AND SUBSIDIARIES UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Form 6 K - Marketscreener.com
CytoMed Therapeutics Reports Six Months Ended June 30, 2024 - GlobeNewswire
CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates - Yahoo Finance
Presenting on the Emerging Growth Conference 75 Day 2 on September 26 - GlobeNewswire
CytoMed Therapeutics Limited acquired the licence and certain assets of Cellsafe International Sdn Bhd from Cellsafe Biotech Group for MYR 2.3 million. - Marketscreener.com
Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now - GlobeNewswire
CytoMed Therapeutics (NASDAQ:GDTC) Trading Down 2% - Defense World
CytoMed Therapeutics Ltd (GDTC) Stock: A Comprehensive 52-Week Review - The InvestChronicle
CytoMed Therapeutics Acquires Cord Blood Banking Licence - GlobeNewswire
CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers - GlobeNewswire
Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now - GlobeNewswire Inc.
CytoMed Therapeutics Limited Announces Board and Audit Committee Changes - Marketscreener.com
CytoMed Therapeutics Limited Announces Collaboration with MD Anderson Cancer Center to Advance Allogeneic Off ... - Quantisnow
CytoMed Therapeutics to Ring Nasdaq Closing Bell - Quantisnow
CytoMed Therapeutics Limited Announces Closing of US$9,649,476 Firm Commitment Initial Public Offering - Quantisnow
CytoMed Therapeutics to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference - Quantisnow
CytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR γδ T In Vivo ... - Quantisnow
A*STAR Spinoff CytoMed Therapeutics Announce a Patent for its Licensed CAR-Gamma Delta T Cell Technology Has ... - Quantisnow
CytoMed Therapeutics : Board re organization Form 6 K - Marketscreener.com
Natural Alternatives International (NASDAQ:NAII) Receives New Coverage from Analysts at StockNews.com - Defense World
Viridian Therapeutics (NASDAQ:VRDN) Receives New Coverage from Analysts at Wolfe Research - Defense World
Anti-aging Therapeutics Market Size, Scope, Growth and Forecast to 2031 - InsightAce Analytic
CytoMed Therapeutics : Annual Shareholders MeetingForm 6-K - Marketscreener.com
CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration - Yahoo Finance
CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies - Marketscreener.com
CytoMed Therapeutics Limited Announces Research - GlobeNewswire
Healthcare Stocks Moving Wednesday: OGEN, FEMY, JSPR, ABEO, GDTC, CING, HUMA, NEXI - InvestorsObserver
Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology - Yahoo Finance
GDTC Stock Price and Chart — NASDAQ:GDTC - TradingView
CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology - PR Newswire
CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update - PR Newswire
Cytomed Therapeutics Limited (GDTC-Q) QuotePress Release - The Globe and Mail
Chinese Patent Granted for CytoMed Therapeutics' Licensed iPSC-Based Technology - PR Newswire
CytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR γδ T In Vivo Persistency - 팜뉴스
Novel T-Cell Immunotherapies Market Share, Size, Growth and Forecast to 2031 - InsightAce Analytic
Why Is CytoMed Therapeutics (GDTC) Stock Up 157% Today? - InvestorPlace
A*STAR Spinoff CytoMed Therapeutics Announce a Patent for its Licensed CAR-Gamma Delta T Cell Technology Has Been Granted in the US - PR Newswire
Cytomed Therapeutics Ltd Azioni (GDTC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
5.11%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):